HRP20180506T1 - Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela - Google Patents

Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela Download PDF

Info

Publication number
HRP20180506T1
HRP20180506T1 HRP20180506TT HRP20180506T HRP20180506T1 HR P20180506 T1 HRP20180506 T1 HR P20180506T1 HR P20180506T T HRP20180506T T HR P20180506TT HR P20180506 T HRP20180506 T HR P20180506T HR P20180506 T1 HRP20180506 T1 HR P20180506T1
Authority
HR
Croatia
Prior art keywords
locus
meganuclease
human
artificial
cell
Prior art date
Application number
HRP20180506TT
Other languages
English (en)
Inventor
Ronald Buelow
Original Assignee
Open Monoclonal Technology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40111008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180506(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Open Monoclonal Technology, Inc. filed Critical Open Monoclonal Technology, Inc.
Publication of HRP20180506T1 publication Critical patent/HRP20180506T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Claims (16)

1. Postupak za ciljanu integraciju umjetnog imunoglobulinskog (Ig) mjesta u primateljskoj ne-humanoj zametnoj stanici, oplođenoj jajnoj stanici ili embrijima, koji obuhvaća: uvođenje u ne-ljudsku zametnu stanicu primatelja, gnojivo jajne stanice ili embrij mjesto specifične meganukleaze usmjerene na endogeni Ig lokus i transgenski vektor koji sadrži umjetni Ig lokus tako da umjetni Ig lokus integrira u genom primateljske ne-humane zametne stanice, oplođene oocite ili embrije ciljanom integracijom i zamjenjuje endogeni Ig lokus ili njihove dijelove homolognim rekombinacijom; gdje meganukleaza povećavaju učestalost homologne rekombinacije kroz dvostruko DNA cijepanje.
2. Postupak sukladno patentnom zahtjevu 1, naznačena time, da je meganukleaza osigurana u konstruktu ekspresije koju je moguće regulirati.
3. Postupak sukladno patentnom zahtjevu 2, naznačena time, da je meganukleaza operativno povezana s inducibilnim promotorom.
4. Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, što se nadalje sastoji od odabira stanice u kojoj je umjetni Ig lokus integriran na ciljano mjesto i u kojem su regulativni konstrukti ekspresije meganukleaze integrirani u genom.
5. Postupak sukladno patentnom zahtjevu 4, naznačena time, da nadalje uključuje spajanje odabrane stanice sa stanicom za nuklearnu prijenosnu jedinicu koja nije ljudska, totipotentna i sposobna za tvorbu funkcionalnog novorođenog tkiva, kako bi se dobila rezultirajuća stanica.
6. Postupak sukladno patentnom zahtjevu 4 ili 5, naznačena time, da je enukleizirana stanična jedinica nuklearnog prijenosa oocit ili embrionalna matična stanica.
7. Postupak sukladno bilo kojem od patentnih zahtjeva 4 do 6, naznačen time, da nadalje sadrži: I. Injektirane odabrane stanice u razvoj ne-ljudskog embrija; ili II. kultiviranje rezultirajuće stanice u odgovarajućem mediju i prenošenje u nastalu stanicu u sinkronizirani primatelj za generiranje transgenične ne-humane životinje.
8. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da umjetni Ig lokus sadrži fragmente ljudskih i ne-humanih Ig-lokusa.
9. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da umjetni Ig lokus sadrži najmanje jedan segment humanog V gena.
10. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da umjetni Ig lokus obuhvaća više segmenata imunoglobulinskog gena, pri čemu segmenti gena sadrže najmanje jedan segment genske regije V, jedan ili više segmenata J, jedan ili više segmenata gena D i jednu ili više konstanta regijskih gena.
11. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da ciljana sekvenca meganukleaze je prisutna u ili proksimalno za segmente gena odabranih od: J segment gena; i genski segment konstantne regije.
12. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da sukladno bilo kojem prethodnom patentnom zahtjevu, nadalje obuhvaća uporabu druge meganukleaze, pri čemu druga meganukleaza prepoznaje drugu ciljnu sekvencu meganukleaze prisutnu u ili proksimalnom endogenom Ig lokusu i selektivno cijepa endogeni Ig lokus zajedno s prvom meganukazom, ali na mjestu različitom od prve meganukleaze, čime se inaktivira najmanje jedan endogeni Ig lokus
13. Transgenska ne-humana životinja, koja se može dobiti metodom sukladno zahtjevu 9, naznačena time, da životinja sadrži: I. najmanje jedan regulirabilni konstrukt genomskog meganukleaza ekspresije; i II. umjetni Ig lokus koji zamjenjuje endogeni Ig lokus; pri čemu je životinja sposobna proizvesti protutijelo koje ima ljudski idiotip.
14. Transgenska životinja sukladno patentnog zahtjevu 13, naznačena time, da je ta životinja odabrana između ptice, glodara, i lasice.
15. Transgenska životinja sukladno patentnom zahtjevu 14, naznačeno time, da je ta životinja štakor.
16. In vitro primjena transgenskog vektora za ciljanu integraciju, pri čemu transgeni vektor sadrži induskcijsku ekspresijsku kontrolnu regiju koju je moguće koja je operabilno povezana s nukleinskom kiselinom koja kodira mjesno specifičnu meganukleazu koja cilja endogeni Ig lokus, pri čemu uporaba obuhvaća: uvođenje transgeničnog vektora u primateljsku ne-ljudsku zametnu stanicu, oplođene oocite ili embrij tako da se transgenski vektor integrira u genom zametne stanice, oplođene oocite ili embrija; i uvođenje transgenskog vektora koji sadrži umjetni Ig lokus u primateljsku ne-humanu zametnu stanicu, oplođeno oocite ili embrij, tako da se umjetni lokus integrira u genom primateljske ne-humane zametne stanice, oplođene oocite ili embrija ciljanom integracijom
HRP20180506TT 2007-06-01 2018-03-27 Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela HRP20180506T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94161907P 2007-06-01 2007-06-01
US4432408P 2008-04-11 2008-04-11
EP12187787.2A EP2602323B1 (en) 2007-06-01 2008-05-30 Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies

Publications (1)

Publication Number Publication Date
HRP20180506T1 true HRP20180506T1 (hr) 2018-05-04

Family

ID=40111008

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180506TT HRP20180506T1 (hr) 2007-06-01 2018-03-27 Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela

Country Status (22)

Country Link
US (6) US8703485B2 (hr)
EP (4) EP3382022A1 (hr)
JP (6) JP5823690B2 (hr)
KR (4) KR101886610B1 (hr)
CN (1) CN101784664B (hr)
AT (1) ATE522611T1 (hr)
AU (1) AU2008259939B2 (hr)
CA (2) CA2688834C (hr)
CY (1) CY1120383T1 (hr)
DK (3) DK2152880T3 (hr)
ES (3) ES2372718T3 (hr)
HK (1) HK1135138A1 (hr)
HR (1) HRP20180506T1 (hr)
HU (1) HUE037302T2 (hr)
IL (2) IL202302A (hr)
LT (1) LT2602323T (hr)
NZ (1) NZ581396A (hr)
PL (3) PL2602323T3 (hr)
PT (3) PT2336329E (hr)
SG (2) SG182144A1 (hr)
SI (1) SI2602323T1 (hr)
WO (1) WO2008151081A1 (hr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512987A (ja) 2004-07-22 2008-05-01 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子
AU2008259939B2 (en) * 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
JP2012501641A (ja) * 2008-09-08 2012-01-26 セレクティス グルタミンシンセターゼ遺伝子からのｄｎａ標的配列を切断するメガヌクレアーゼ変異型及びその使用
LT2346994T (lt) * 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
CN102625655B (zh) * 2008-12-04 2016-07-06 桑格摩生物科学股份有限公司 使用锌指核酸酶在大鼠中进行基因组编辑
RU2011129459A (ru) * 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
KR101553244B1 (ko) 2009-12-10 2015-09-15 리제너론 파마슈티칼스 인코포레이티드 중쇄 항체를 만드는 마우스
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9580491B2 (en) 2010-03-31 2017-02-28 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
CN103228130B (zh) * 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CA2806233C (en) 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
NZ606824A (en) 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
EP3345922A1 (en) 2011-03-09 2018-07-11 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
WO2012149470A1 (en) * 2011-04-27 2012-11-01 Amyris, Inc. Methods for genomic modification
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
JP2014533930A (ja) * 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
CN103917644A (zh) 2011-09-21 2014-07-09 桑格摩生物科学股份有限公司 调控转基因表达的方法和组合物
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SG10202010120XA (en) 2011-10-17 2020-11-27 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
ES2683071T3 (es) 2012-04-25 2018-09-24 Regeneron Pharmaceuticals, Inc. Direccionamiento mediado por nucleasas con grandes vectores de direccionamiento
BR112014031080A2 (pt) * 2012-06-12 2018-05-08 Genentech Inc métodos e composições de geração de alelos knock-out condicionais.
KR102436654B1 (ko) 2012-06-12 2022-08-26 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
PT2931030T (pt) * 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
LT2840892T (lt) 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
RS62263B1 (sr) 2013-04-16 2021-09-30 Regeneron Pharma Ciljana modifikacija genoma pacova
EP2986709A4 (en) * 2013-04-16 2017-03-15 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
RU2725520C2 (ru) 2013-12-11 2020-07-02 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
MX2016014210A (es) 2014-04-30 2017-05-01 Hanall Biopharma Co Ltd Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3708671A1 (en) 2014-06-06 2020-09-16 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
US9902971B2 (en) 2014-06-26 2018-02-27 Regeneron Pharmaceuticals, Inc. Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
SI3221457T1 (sl) 2014-11-21 2019-08-30 Regeneron Pharmaceuticals, Inc. Postopki in sestavki za ciljno genetsko modifikacijo z uporabo vodilnih RNK v parih
WO2016100819A1 (en) 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
JP6883579B2 (ja) 2015-08-11 2021-06-09 ウーシー バイオロジクス（ケイマン）インコーポレイテッド 新規抗ｐｄ−１抗体
WO2017035241A1 (en) 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
DK3411476T3 (da) 2016-02-04 2024-07-15 Trianni Inc Forøget produktion af immunoglobuliner
CA3026088A1 (en) 2016-06-03 2017-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
CR20220408A (es) 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Antibodies against BCMA containing only heavy chains and their uses
AR110414A1 (es) 2016-12-21 2019-03-27 Cephalon Inc Anticuerpos que se unen específicamente a il-15 humana y usos de estos
WO2018136823A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2019051164A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
WO2019055689A1 (en) 2017-09-13 2019-03-21 Teneobio, Inc. HEAVY CHAIN ANTIBODIES BINDING TO EXOENZYMES
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
JOP20200157A1 (ar) 2017-12-22 2022-10-30 Teneobio Inc أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
WO2019133761A1 (en) 2017-12-27 2019-07-04 Teneobio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
WO2019190922A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
EP3813520A4 (en) * 2018-06-13 2022-03-23 Crystal Bioscience Inc. TRANSGENIC CHICKEN STABILIZING LONG CDR-H3S ANTIBODIES BY MEANS OF MULTIPLE DISULPHIDE BRIDGES AND DIVERSIFIED BY GENE CONVERSION
US12102070B2 (en) * 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL305557A (en) 2018-06-14 2023-10-01 Regeneron Pharma Non-human animals with transgenic DH–DH rearrangement capacity, and their uses
KR20210032311A (ko) 2018-07-20 2021-03-24 테네오바이오, 인코포레이티드 Cd19에 결합하는 중쇄 항체
MX2021001305A (es) 2018-08-01 2021-06-23 Cephalon Inc Anticuerpos anti-cxcr2 y usos de los mismos.
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
AU2020211728A1 (en) 2019-01-23 2021-08-12 Encefa CD31 competitors and uses thereof
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
CN114630838A (zh) 2019-05-20 2022-06-14 法国国家健康和医学研究院 新的抗cd25抗体
CA3140816A1 (en) 2019-06-14 2020-12-17 Nathan Trinklein Multispecific heavy chain antibodies binding to cd22 and cd3
EP4034561A2 (en) 2019-09-27 2022-08-03 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
JP2023504172A (ja) 2019-12-02 2023-02-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
JP2023526774A (ja) 2020-04-29 2023-06-23 テネオバイオ， インコーポレイテッド 重鎖定常領域が修飾された多重特異性重鎖抗体
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals Beijing Co Ltd GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4247496A1 (en) 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
EP4247497A1 (en) 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-cd25 antibodies
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing human FC alpha receptors
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
WO2023170207A1 (en) 2022-03-09 2023-09-14 Alderaan Biotechnology Anti-cd160 transmembrane isoform antibodies
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) * 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
AU8212291A (en) 1990-07-10 1992-02-04 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE4119749A1 (de) 1991-06-15 1992-12-17 Claas Ohg Verfahren zum entholzen von flachs und flachsaufbereitungsmaschine zur durchfuehrung dieses verfahrens
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US5795974A (en) 1993-12-10 1998-08-18 University Of Utah Research Foundation Mycoplasma arthritidis superantigen
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
KR20080059467A (ko) * 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
JP2002533130A (ja) * 1998-12-31 2002-10-08 ザ ジェイ． デビッド グラッドストーン インスティテューツ Ｈｉｖ共受容体を発現するトランスジェニック齧歯類動物および齧歯類細胞株
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2004500843A (ja) * 2000-04-24 2004-01-15 ワイエス トランスジェニック動物
AU2001284703B2 (en) * 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP2005502341A (ja) 2001-08-20 2005-01-27 メルク　エンド　カムパニー　インコーポレーテッド Ｂ１ブラジキニン受容体タンパク質を調節するための動物モデルとしてのトランスジェニックげっ歯類
WO2003025183A2 (en) * 2001-09-14 2003-03-27 Cellectis Random integration of a polynucleotide after in vivo linearization
EP3269235B1 (en) 2001-11-30 2022-01-26 Amgen Fremont Inc. Transgenic mice bearing human ig lambda light chain genes
ES2292994T3 (es) 2002-03-15 2008-03-16 Cellectis Meganucleasas hibridas y de cadena sencilla y su utilizacion.
EP2368982A3 (en) * 2002-03-21 2011-10-12 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
EP2522723B1 (en) 2003-01-28 2014-12-03 Cellectis Custom-made meganuclease and use thereof
WO2004072115A2 (en) * 2003-02-05 2004-08-26 Therapeutic Human Polyclonals, Inc. Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
CA2529623A1 (en) * 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005019463A1 (en) * 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
WO2005038001A2 (en) * 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
EP1726640B1 (en) 2004-03-04 2016-01-13 Sumitomo Dainippon Pharma Co., Ltd. Rat embryonic stem cell
JP2008512987A (ja) 2004-07-22 2008-05-01 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子
CN101084317A (zh) * 2004-10-22 2007-12-05 人类多克隆治疗公司 对内源免疫球蛋白表达的抑制
US20060130157A1 (en) * 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
WO2006093337A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP2325307A1 (en) 2005-03-15 2011-05-25 Cellectis I-crel meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
US7491866B2 (en) 2005-11-09 2009-02-17 Board Of Regents University Of Texas System Transgenic rats and spermatogonial stem cells
KR101481843B1 (ko) 2006-01-25 2015-01-12 에라스무스 유니버시티 메디컬 센터 로테르담 형질전환 동물 내에서의 중쇄만의 항체의 생성
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
AU2008259939B2 (en) * 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
LT2840892T (lt) * 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis

Also Published As

Publication number Publication date
KR20150101475A (ko) 2015-09-03
JP2020125360A (ja) 2020-08-20
AU2008259939A1 (en) 2008-12-11
SG182144A1 (en) 2012-07-30
JP5823690B2 (ja) 2015-11-25
EP3382022A1 (en) 2018-10-03
WO2008151081A1 (en) 2008-12-11
EP2152880A4 (en) 2010-06-16
IL202302A0 (en) 2011-08-01
PL2152880T3 (pl) 2012-03-30
EP2336329B1 (en) 2012-10-10
JP6220827B2 (ja) 2017-10-25
JP6712254B2 (ja) 2020-06-17
EP2152880A1 (en) 2010-02-17
US8907157B2 (en) 2014-12-09
DK2152880T3 (da) 2011-11-28
KR101661357B1 (ko) 2016-09-29
HUE037302T2 (hu) 2018-08-28
KR20170016518A (ko) 2017-02-13
NZ581396A (en) 2012-07-27
JP2015204840A (ja) 2015-11-19
US20160311888A1 (en) 2016-10-27
JP2018000201A (ja) 2018-01-11
CA3054224A1 (en) 2008-12-11
EP2336329B8 (en) 2012-11-21
US20090098134A1 (en) 2009-04-16
EP2602323B1 (en) 2018-02-28
HK1135138A1 (en) 2010-05-28
JP2010529042A (ja) 2010-08-26
US20210253673A1 (en) 2021-08-19
CN101784664A (zh) 2010-07-21
ES2664218T3 (es) 2018-04-18
PT2336329E (pt) 2012-12-24
CY1120383T1 (el) 2019-07-10
IL202302A (en) 2013-07-31
SG10201509853UA (en) 2015-12-30
KR20100037027A (ko) 2010-04-08
DK2336329T3 (da) 2013-01-07
US10072069B2 (en) 2018-09-11
US8703485B2 (en) 2014-04-22
US20100212035A1 (en) 2010-08-19
JP2014027947A (ja) 2014-02-13
PT2602323T (pt) 2018-04-02
CA2688834A1 (en) 2008-12-11
LT2602323T (lt) 2018-04-10
SI2602323T1 (en) 2018-05-31
EP2152880B1 (en) 2011-08-31
KR102096731B1 (ko) 2020-04-02
US20120090041A1 (en) 2012-04-12
KR101703299B1 (ko) 2017-02-06
IL220209A (en) 2013-11-28
EP2602323A1 (en) 2013-06-12
ES2393826T3 (es) 2012-12-28
IL220209A0 (en) 2012-07-31
AU2008259939B2 (en) 2014-03-13
US9388233B2 (en) 2016-07-12
ES2372718T3 (es) 2012-01-25
PT2152880E (pt) 2011-12-15
US20190169270A1 (en) 2019-06-06
JP2022118217A (ja) 2022-08-12
KR101886610B1 (ko) 2018-08-09
PL2336329T3 (pl) 2013-04-30
DK2602323T3 (en) 2018-04-16
EP2336329A1 (en) 2011-06-22
ATE522611T1 (de) 2011-09-15
CN101784664B (zh) 2013-04-10
PL2602323T3 (pl) 2018-06-29
KR20180090395A (ko) 2018-08-10
WO2008151081A8 (en) 2010-02-04
CA2688834C (en) 2020-01-07
CN102850452A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
HRP20180506T1 (hr) Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela
Kuroiwa et al. Cloned transchromosomic calves producing human immunoglobulin
Dyck et al. Making recombinant proteins in animals–different systems, different applications
Cooper et al. Innovative approaches to genome editing in avian species
ES2827482T3 (es) Uso de un ratón para producir anticuerpos híbridos que contienen regiones variables humanas y regiones constantes de ratón como fuente de ADN que codifica una región variable humana de dicho anticuerpo
US7105348B2 (en) Methods of modifying eukaryotic cells
BR112014026294B1 (pt) Método para modificar um lócus genômico alvo em uma célula tronco embrionária (es) de camundongo
CN111471719A (zh) 有效的非减数分裂等位基因渐渗
KR20200093570A (ko) 조작된 면역글로불린 람다 경쇄를 갖는 비-인간 동물 및 그의 용도
Doran et al. Advances in genetic engineering of the avian genome:“Realising the promise”
Tizard et al. Potential benefits of gene editing for the future of poultry farming
CN105658050A (zh) 用于制备具有可分选精子的动物的遗传技术
CN109112159A (zh) 基于Cas9介导的定点整合FABP4基因和MSTN基因点突变打靶载体及重组细胞
CA2501415A1 (en) Method of selecting cells for somatic cell nuclear transfer
CA2300972A1 (en) Use of mariner transposan in the production of transgenic animals
Liu et al. Site-directed gene integration in transgenic zebrafish mediated by cre recombinase using a combination of mutant lox sites
Zou et al. Dominant expression of a 1.3 Mb human Igk locus replacing mouse light chain production
JP7426120B2 (ja) ノックイン細胞の作製方法
KR20210106412A (ko) 유전적으로 변형된 불임 조류 및 이의 재구성 방법
CN106978416A (zh) 一种基因定位整合表达系统及其应用
US20190045761A1 (en) Inducible disease models methods of making them and use in tissue complementation
Duncan et al. Chromosomal engineering
Cyriac et al. Transgenic chicken: methods and applications.
CN114606270B (zh) 一种Mia3条件性基因敲除小鼠模型的构建方法
KR101724805B1 (ko) 유전자 적중 물질을 이용한 조류 유전자 편집방법 및 유전자 편집 조류